{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T22:39:21Z","timestamp":1787006361992,"version":"build-2736575974"},"reference-count":22,"publisher":"Informa UK Limited","issue":"3","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"EMD Serono Inc. (an affiliate of Merck KGaA, Darmstadt, Germany"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2021,3,4]]},"DOI":"10.1080\/03007995.2020.1865888","type":"journal-article","created":{"date-parts":[[2020,12,17]],"date-time":"2020-12-17T16:21:44Z","timestamp":1608222104000},"page":"459-464","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":14,"title":["Efficacy of cladribine tablets in high disease activity patients with relapsing multiple sclerosis:\n                    <i>post hoc<\/i>\n                    analysis of subgroups with and without prior disease-modifying drug treatment"],"prefix":"10.1080","volume":"37","author":[{"given":"Patrick","family":"Vermersch","sequence":"first","affiliation":[{"name":"Inserm U1172, CHU Lille, FHU Imminent, University of Lille, Lille, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Galazka","sequence":"additional","affiliation":[{"name":"Ares Trading S.A., Eysins, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Dangond","sequence":"additional","affiliation":[{"name":"EMD Serono Research & Development Institute Inc., Billerica, MA, USA, a business of Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doris","family":"Damian","sequence":"additional","affiliation":[{"name":"EMD Serono Research & Development Institute Inc., Billerica, MA, USA, a business of Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Schiffon L.","family":"Wong","sequence":"additional","affiliation":[{"name":"EMD Serono Research & Development Institute Inc., Billerica, MA, USA, a business of Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominic","family":"Jack","sequence":"additional","affiliation":[{"name":"Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerard","family":"Harty","sequence":"additional","affiliation":[{"name":"Merck KGaA, Darmstadt, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2021,2,1]]},"reference":[{"key":"CIT0001","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2019.11.018"},{"key":"CIT0002","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2016-013430"},{"key":"CIT0003","doi-asserted-by":"publisher","DOI":"10.1177\/1352458510394454"},{"key":"CIT0004","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0231846"},{"key":"CIT0005","doi-asserted-by":"publisher","DOI":"10.1177\/1756285615598910"},{"key":"CIT0006","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2016.07.003"},{"key":"CIT0007","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2017.23.8.844"},{"key":"CIT0008","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2017.07.003"},{"key":"CIT0009","unstructured":"eMC. Mavenclad 10mg tablets [Internet]. London (UK): EMC; 2017 [cited 2017 Dec 18]. Available from: https:\/\/www.medicines.org.uk\/emc\/medicine\/34044"},{"key":"CIT0010","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0902533"},{"key":"CIT0011","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(11)70023-0"},{"key":"CIT0012","doi-asserted-by":"publisher","DOI":"10.1177\/1352458518771875"},{"key":"CIT0013","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2017.1407303"},{"key":"CIT0014","doi-asserted-by":"publisher","DOI":"10.1002\/ana.20703"},{"key":"CIT0015","doi-asserted-by":"publisher","DOI":"10.1080\/105294199277860"},{"key":"CIT0016","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102572"},{"key":"CIT0017","doi-asserted-by":"publisher","DOI":"10.1002\/ana.23758"},{"key":"CIT0018","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(09)70082-1"},{"key":"CIT0019","doi-asserted-by":"publisher","DOI":"10.1016\/j.ncl.2011.01.001"},{"key":"CIT0020","doi-asserted-by":"publisher","DOI":"10.1007\/s40120-019-0129-0"},{"key":"CIT0021","unstructured":"Guideline on clinical investigation of medicinal products for the treatment of multiple sclerosis. Amsterdam (The Netherlands): European Medicine Agency; 2015."},{"issue":"16","key":"CIT0022","volume":"86","author":"Giovannoni G","year":"2016","journal-title":"Neurology"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2020.1865888","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,19]],"date-time":"2021-03-19T03:25:09Z","timestamp":1616124309000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2020.1865888"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,1]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3,4]]}},"alternative-id":["10.1080\/03007995.2020.1865888"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2020.1865888","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,1]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2020-11-12","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-14","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-12-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-02-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}